Skip to main content

Abbott Laboratories income statement

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B

Abbott Laboratories reported revenue of $44.3 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 5.7% from fiscal 2024. Net income was $6.52 billion and diluted earnings per share $3.72.

From Abbott Laboratories's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Abbott Laboratories income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$25.91B$29.53B$30.76B$35.17B$21.41B$19.05B$19.66B$20.25B$20.41B$20.85B$27.39B$30.58B$31.90B$34.61B$43.08B$43.65B$40.11B$41.95B$44.33B$48.23B
Revenue growth—+13.9%+4.2%+14.3%−39.1%−11.0%+3.2%+3.0%+0.8%+2.2%+31.3%+11.6%+4.3%+8.5%+24.5%+1.3%−8.1%+4.6%+5.7%—
Cost of revenue$11.42B$12.61B$13.21B$14.67B$10.02B$8.90B$9.19B$9.22B$8.75B$9.09B$12.41B$12.71B$13.23B$15.00B$18.54B$19.14B$17.98B$18.71B$19.32B$20.77B
Gross profit$14.49B$16.92B$17.56B$20.50B$11.39B$10.15B$10.46B$11.03B$11.66B$11.76B$14.98B$17.87B$18.67B$19.61B$24.54B$24.51B$22.13B$23.24B$25.01B$27.46B
Gross margin55.9%57.3%57.1%58.3%53.2%53.3%53.2%54.5%57.1%56.4%54.7%58.4%58.5%56.6%57.0%56.1%55.2%55.4%56.4%56.9%
Research and development——————————$2.26B$2.30B$2.44B$2.42B$2.74B$2.89B$2.74B$2.84B$2.94B$3.31B
Selling, general and administrative$7.41B$8.44B$8.41B$10.38B$7.37B$6.74B$6.37B$6.53B$6.79B$6.74B$9.18B$9.74B$9.77B$9.70B$11.32B$11.25B$10.95B$11.70B$12.33B$15.16B
Operating income$4.58B$5.69B$6.24B$6.09B$1.63B$1.36B$2.13B$2.60B$2.87B$3.03B$1.56B$3.65B$4.53B$5.36B$8.43B$8.36B$6.48B$6.83B$8.05B$6.65B
Operating margin17.7%19.3%20.3%17.3%7.6%7.1%10.9%12.8%14.1%14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%13.8%
Interest expense$593.1M$528.5M$519.7M$553.1M$359.0M$320.0M$145.0M$150.0M$163.0M$431.0M$904.0M$826.0M$670.0M$546.0M$533.0M$558.0M$637.0M$559.0M$493.0M$995.0M
Income before tax$4.47B$6.00B$7.19B$5.71B$1.24B−$220.0M$2.04B$2.52B$3.18B$1.41B$2.23B$2.87B$4.08B$4.97B$8.21B$8.31B$6.66B$7.01B$8.47B$6.56B
Income tax expense$863.3M$1.12B$1.45B$1.09B$110.0M−$457.0M$53.00M$797.0M$577.0M$350.0M$1.88B$539.0M$390.0M$497.0M$1.14B$1.37B$941.0M−$6.39B$1.94B$1.86B
Effective tax rate19.3%18.7%20.1%19.0%8.9%208%2.6%31.7%18.1%24.8%84.2%18.8%9.6%10.0%13.9%16.5%14.1%−91.1%22.9%28.4%
Net income$3.61B$4.88B$5.75B$4.63B$4.71B$5.96B$2.58B$2.28B$4.42B$1.40B$477.0M$2.37B$3.69B$4.50B$7.07B$6.93B$5.72B$13.40B$6.52B$4.70B
Net margin13.9%16.5%18.7%13.2%22.0%31.3%13.1%11.3%21.7%6.7%1.7%7.7%11.6%13.0%16.4%15.9%14.3%31.9%14.7%9.7%
Net income to common shareholders——$5.75B$4.63B$4.71B$5.92B$2.56B$2.27B$4.40B$1.39B$468.0M$2.35B$3.67B$4.47B$7.04B$6.91B$5.70B$13.40B$6.50B$4.70B
EPS · diluted$2.31$3.12$3.69$2.96$3.01$3.72$1.62$1.49$2.92$0.94$0.27$1.33$2.06$2.50$3.94$3.91$3.26$7.64$3.72$2.70
Diluted weighted average shares1.6B1.6B1.6B1.6B1.6B1.6B1.6B1.5B1.5B1.5B1.7B1.8B1.8B1.8B1.8B1.8B1.7B1.7B1.7B1.7B
Basic weighted average shares1.5B1.5B1.5B1.5B1.6B1.6B1.6B1.5B1.5B1.5B1.7B1.8B1.8B1.8B1.8B1.8B1.7B1.7B1.7B1.7B
EBITDA$6.43B$7.53B$8.33B$8.71B$4.67B$4.14B$3.85B$4.15B$4.34B$4.38B$4.58B$6.93B$7.55B$8.68B$11.96B$11.63B$9.72B$10.04B$11.17B$10.56B
EBITDA margin24.8%25.5%27.1%24.8%21.8%21.7%19.6%20.5%21.3%21.0%16.7%22.7%23.7%25.1%27.8%26.6%24.2%23.9%25.2%21.9%
Depreciation & amortization$1.85B$1.84B$2.09B$2.62B$3.04B$2.78B$1.72B$1.55B$1.47B$1.35B$3.02B$3.28B$3.01B$3.33B$3.54B$3.27B$3.24B$3.22B$3.12B$3.91B
Stock-based compensation$429.7M$347.0M$366.4M$387.2M$383.0M$433.0M$262.0M$246.0M$292.0M$310.0M$406.0M$477.0M$519.0M$546.0M$640.0M$685.0M$644.0M$673.0M$664.0M$735.0M
Dividends per share——$1.60$1.76$1.92——————————$1.92$2.08$2.24$2.40$2.52

Quarterly

Abbott Laboratories income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$10.24B$9.96B$10.38B$10.63B$10.97B$10.36B$11.14B$11.37B$11.46B$11.16B$12.59B$13.01B
Cost of revenue$4.56B$4.46B$4.60B$4.70B$4.94B$4.47B$4.85B$5.08B$4.92B$4.89B$5.33B$5.63B
Gross profit$5.68B$5.50B$5.77B$5.94B$6.03B$5.89B$6.29B$6.29B$6.54B$6.27B$7.27B$7.38B
Gross margin55.5%55.2%55.6%55.8%55.0%56.9%56.4%55.4%57.0%56.2%57.7%56.8%
Research and development$700.0M$684.0M$698.0M$713.0M$749.0M$716.0M$725.0M$766.0M$735.0M$767.0M$892.0M$920.0M
Selling, general and administrative$2.72B$2.96B$2.94B$2.90B$2.91B$3.06B$3.09B$3.05B$3.13B$3.74B$4.03B$4.27B
Operating income$1.78B$1.39B$1.67B$1.86B$1.91B$1.69B$2.05B$2.06B$2.25B$1.34B$1.69B$1.36B
Operating margin17.4%13.9%16.1%17.5%17.4%16.3%18.4%18.1%19.6%12.0%13.4%10.4%
Interest expense$159.0M$141.0M$140.0M$142.0M$136.0M$131.0M$121.0M$121.0M$120.0M$174.0M$351.0M$350.0M
Income before tax$1.79B$1.44B$1.61B$1.94B$2.03B$1.78B$2.15B$2.18B$2.36B$1.45B$1.52B$1.23B
Income tax expense$201.0M$211.0M$305.0M$294.0M−$7.20B$453.0M$371.0M$536.0M$582.0M$372.0M$596.0M$311.0M
Effective tax rate11.2%14.7%19.0%15.2%−355%25.5%17.3%24.6%24.7%25.7%39.1%25.3%
Net income$1.59B$1.23B$1.30B$1.65B$9.23B$1.32B$1.78B$1.64B$1.78B$1.08B$928.0M$920.0M
Net margin15.6%12.3%12.5%15.5%84.1%12.8%16.0%14.5%15.5%9.6%7.4%7.1%
Net income to common shareholders$1.59B—$1.30B—$9.20B———$1.80B———
EPS · diluted$0.91$0.70$0.74$0.94$5.28$0.76$1.01$0.94$1.03$0.61$0.53$0.53
Diluted weighted average shares1.7B1.7B1.8B1.7B1.7B1.7B1.8B1.7B1.7B1.7B1.7B1.7B
Basic weighted average shares1.7B1.7B1.7B1.7B1.7B1.7B1.7B1.7B1.7B1.7B1.7B1.7B
EBITDA$2.59B$2.19B$2.47B$2.66B$2.72B$2.45B$2.83B$2.85B$3.04B$2.15B$2.75B$2.61B
EBITDA margin25.3%22.0%23.8%25.0%24.8%23.6%25.4%25.1%26.6%19.2%21.9%20.1%
Depreciation & amortization$813.0M$805.0M$805.0M$801.0M$807.0M$756.0M$777.0M$791.0M$792.0M$803.0M$1.06B$1.26B
Stock-based compensation$114.0M$304.0M$141.0M$117.0M$111.0M$289.0M$142.0M$120.0M$113.0M$317.0M$168.0M$137.0M
Dividends per share$0.55$0.55$0.55$0.55$0.59$0.59$0.59$0.59$0.63$0.63$0.63$0.63

The main figures as JSON and plain text. See data and methodology.

ABT in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.